1-3 of 3
Mazen W. Karaman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl D. Cramer, Michael F. Gardner, Daniel Brigham, Barbara Belli, Mazen W. Karaman, Keith W. Pratz, Gabriel Pallares, Qi Chao, Kelly G. Sprankle, Hitesh K. Patel, Mark Levis, Robert C. Armstrong, Joyce James, Shripad S. Bhagwat
Journal: Blood
Blood (2009) 114 (14): 2984–2992.
https://doi.org/10.1182/blood-2009-05-222034
Published: 2009
Includes: Supplemental data
Journal Articles

AC220 Is a Uniquely Potent and Selective Second-Generation FLT3 Inhibitor

Patrick P Zarrinkar, PhD, Robert C Armstrong, Ph.D., Ruwanthi N Gunawardane, Ph.D., Joyce James, PhD, Mazen W Karaman, Ph.D., Shripad S Bhagwat, PhD
Journal: Blood
Blood (2008) 112 (11): 859.
https://doi.org/10.1182/blood.V112.11.859.859
Published: 2008
Journal Articles

Motexafin Gadolinium Causes Apoptosis in Lymphoma Cells by Increasing Intracellular Free Zinc and Disrupting Redox Balance.

Darren Magda, PhD, Philip Lecane, PhD, Mazen W. Karaman, PhD, Mint Sirisawad, PhD, Louie Naumovski, MD, PhD, Richard A. Miller, MD, Joseph G. Hacia, PhD
Journal: Blood
Blood (2005) 106 (11): 4827.
https://doi.org/10.1182/blood.V106.11.4827.4827
Published: 2005